Recep Tayyip Erdoğan University Institutional Repository
metadata only
Targeting ceramide metabolism to overcome osimertinib resistance in egfr-mutant non-small cell lung cancer: an in vitro, network pharmacology, and in silico study
Introduction: Osimertinib, an irreversible epidermal growth factor receptor inhibitor, is recognized for use in non-small cell lung cancer patients with the T790M resistance mutation. Though osimertinib offers a valuable advantage in survival of the patients, the occurrence of acquired resistance me
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma#869896
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer#834044
- Osimertinib In EGFR Mutant Lung Cancer#968854
- Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC#1350181
- A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations#1262097
Record · ID 1391704
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive